Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D H Ho

Showing results (41-50 of 117) with videos related to

Pageof 12
Sort By:
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 1, 1990
Comparative in vitro activity of the new erythromycin derivative dirithromycin against gram-positive bacteria isolated from cancer patientsK V Rolston, D H Ho, B LeBlanc, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|October 1, 1988
Comparative in vitro activity of the two new 4-quinolones S-25930 and S-25932 against gram-positive bacteria isolated from cancer patientsK V Rolston, D H Ho, B LeBlanc, et al.
Antimicrobial Agents and Chemotherapy|November 1, 1993
In vitro activities of antimicrobial agents against clinical isolates of Flavimonas oryzihabitans obtained from patients with cancerK V Rolston, D H Ho, B LeBlanc, et al.
Chemotherapy|January 1, 1990
In vitro activity of PD127,391, a new quinolone against bacterial isolates from cancer patientsK V Rolston, D H Ho, B LeBlanc, et al.
Antimicrobial Agents and Chemotherapy|April 1, 1987
In vitro activity of paldimycin (U-70138F) against gram-positive bacteria isolated from patients with cancerK V Rolston, B LeBlanc, D H Ho, et al.
Anti-Cancer Drugs|September 1, 1996
Phase I trials of uracil-tegafur (UFT) using 5 and 28 day administration schedules: demonstration of schedule-dependent toxicitiesR Pazdur, Y Lassere, E Diaz-Canton, et al.
Cancer Research|January 1, 1981
Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-beta-D-arabinofuranosylcytosineJ P Bergerat, B Drewinko, P Corry, et al.
Antimicrobial Agents and Chemotherapy|April 1, 1981
Clinical pharmacology of moxalactam in patients with malignant diseaseE H Estey, S S Weaver, D H Ho, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 1, 1987
Effects of cisplatin-induced nephrotoxicity on gentamicin pharmacokinetics in ratsM S Engineer, G P Bodey, R A Newman, et al.
The Journal of Antimicrobial Chemotherapy|June 1, 1997
In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancerK V Rolston, D H Ho, B LeBlanc, et al.
Pageof 12

Showing results (41-50 of 117) with videos related to

Sort By:
Pageof 12
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 1, 1990
Comparative in vitro activity of the new erythromycin derivative dirithromycin against gram-positive bacteria isolated from cancer patientsK V Rolston, D H Ho, B LeBlanc, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|October 1, 1988
Comparative in vitro activity of the two new 4-quinolones S-25930 and S-25932 against gram-positive bacteria isolated from cancer patientsK V Rolston, D H Ho, B LeBlanc, et al.
Antimicrobial Agents and Chemotherapy|November 1, 1993
In vitro activities of antimicrobial agents against clinical isolates of Flavimonas oryzihabitans obtained from patients with cancerK V Rolston, D H Ho, B LeBlanc, et al.
Chemotherapy|January 1, 1990
In vitro activity of PD127,391, a new quinolone against bacterial isolates from cancer patientsK V Rolston, D H Ho, B LeBlanc, et al.
Antimicrobial Agents and Chemotherapy|April 1, 1987
In vitro activity of paldimycin (U-70138F) against gram-positive bacteria isolated from patients with cancerK V Rolston, B LeBlanc, D H Ho, et al.
Anti-Cancer Drugs|September 1, 1996
Phase I trials of uracil-tegafur (UFT) using 5 and 28 day administration schedules: demonstration of schedule-dependent toxicitiesR Pazdur, Y Lassere, E Diaz-Canton, et al.
Cancer Research|January 1, 1981
Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-beta-D-arabinofuranosylcytosineJ P Bergerat, B Drewinko, P Corry, et al.
Antimicrobial Agents and Chemotherapy|April 1, 1981
Clinical pharmacology of moxalactam in patients with malignant diseaseE H Estey, S S Weaver, D H Ho, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 1, 1987
Effects of cisplatin-induced nephrotoxicity on gentamicin pharmacokinetics in ratsM S Engineer, G P Bodey, R A Newman, et al.
The Journal of Antimicrobial Chemotherapy|June 1, 1997
In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancerK V Rolston, D H Ho, B LeBlanc, et al.
Pageof 12